A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

PHASE1CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

November 26, 2020

Primary Completion Date

August 25, 2025

Study Completion Date

August 25, 2025

Conditions
Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia
Interventions
DRUG

JNJ-74856665

JNJ-74856665 will be administered orally.

DRUG

AZA

AZA will be administered IV infusion or SC injection.

DRUG

VEN

VEN tablet will be administered orally.

Trial Locations (20)

3080

Seoul National University Hospital, Seoul

28040

Hosp Univ Fund Jimenez Diaz, Madrid

31008

Clinica Univ. de Navarra, Pamplona

31059

Institut Universitaire du Cancer Toulouse Oncopole, Toulouse

33600

Centre Hospitalier Universitaire (CHU) de Bordeaux Hopital HautLeveque Centre Francois Magendie, Pessac

37000

CHRU Tours Hopital Bretonneau, Tours

39008

Hosp. Univ. Marques de Valdecilla, Santander

75010

Hopital Saint Louis, Paris

06200

CHU de Nice Hopital de l Archet, Nice

03722

Severance Hospital Yonsei University Health System, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

06591

The Catholic University of Korea Seoul St Marys Hospital, Seoul

08035

Hosp Univ Vall D Hebron, Barcelona

08036

Hosp Clinic de Barcelona, Barcelona

08908

Inst. Cat. Doncologia-H Duran I Reynals, Barcelona

LE1 5WW

Leicester Royal Infirmary, Leicester

NW1 2BU

University College London Hospitals, London

SE5 9RF

Kings College Hospital, London

M20 4BX

The Christie Nhs Foundation Trust, Manchester

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04609826 - A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Biotech Hunter | Biotech Hunter